ArticleInternational urology and nephrology2026
Revisiting the clinical predictors of avascular necrosis after kidney transplantation.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAvascular necrosis (AVN) is a debilitating bone complication that may occur after kidney transplantation (KT), often associated with corticosteroid use. This study aimed to evaluate the prevalence of AVN, identify its risk factors, assess associations with immunosuppressive agents, determine lateralization relative to the allograft, and review treatment methods.
methodsDemographic and clinical data, including donor type, primary kidney disease, immunosuppressive therapies, and details on AVN were evaluated.
resultsThis study retrospectively analyzed 421 KTs. The overall AVN prevalence was 8.3% (n = 35), with the femoral head being the most commonly affected site (85.7%). The prevalence of AVN significantly declined from 21.2% before 2000 to 7.2% after 2000 (p = 0.005). Cumulative steroid doses at post-transplant months 3 and 12 were significantly higher in the AVN group (p = 0.002 and p = 0.003, respectively). Cox regression revealed that glomerulonephritis as primary kidney disease (Hazard Ratio [HR]: 3.12; 95% Confidence Interval [CI]: 1.46-6.69; p = 0.003), acute rejection (HR: 6.59; 95% CI: 1.6-27.01; p = 0.009), and azathioprine (AZA) use (HR: 2.49; 95% CI: 1.14-5.46; p = 0.022) were independent risk factors for AVN development.
conclusionsGlomerulonephritis, acute rejection, and AZA use, largely linked to corticosteroid exposure, are significant contributors to AVN after KT. The introduction of tacrolimus post-2000 was associated with a notable reduction in AVN prevalence, reinforcing the importance of optimized immunosuppressive protocols.
Indexed as
Identifiers
41484517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.